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Abstract
Objective. To determine whether MPO contributes to oxidative stress and disease activity in RA and
whether it produces hypochlorous acid in SF.
Methods. Plasma and where possible SF were collected from 77 RA patients while 120 healthy controls
supplied plasma only. MPO and protein carbonyls were measured by ELISAs. 3-Chlorotyrosine in proteins
and allantoin in plasma were measured by mass spectrometry.
Results. Plasma MPO concentrations were significantly higher in patients with RA compared with
healthy controls [10.8 ng/ml, inter-quartile range (IQR): 7.214.2; P< 0.05], but there was no significant
difference in plasma MPO protein concentrations between RA patients with high disease activity
(HDA; DAS-28 >3.2) and those with low disease activity (LDA; DAS-28 43.2) (HDA 27.9 ng/ml,
20.234.1 vs LDA 22.1 ng/ml, 16.934.9; P>0.05). There was a significant relationship between plasma
MPO and DAS-28 (r= 0.35; P= 0.005). Plasma protein carbonyls and allantoin were significantly higher in
patients with RA compared with the healthy controls. MPO protein was significantly higher in SF com-
pared with plasma (median 624.0 ng/ml, IQR 258.42433.0 vs 30.2 ng/ml, IQR 25.150.9; P< 0.0001). The
MPO present in SF was mostly active. 3-Chlorotyrosine, a specific biomarker of hypochlorous acid, was
present in proteins from SF and related to the concentration of MPO (r= 0.69; P= 0.001). Protein carbonyls
in SF were associated with MPO protein concentration (r= 0.40; P= 0.019) and 3-chlorotyrosine (r= 0.66;
P= 0.003).
Conclusion. MPO is elevated in patients with RA and promotes oxidative stress through the production of
hypochlorous acid.
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Introduction
RA is a chronic inflammatory disease characterized by
synovial and systemic inflammation. The inflamed syno-
vium is infiltrated by neutrophils, macrophages, T cells
and B cells, which release a variety of pro-inflammatory
mediators [1]. Persistent inflammation results in destruc-
tion of cartilage and bone. This occurs through a number
of mechanisms, including oxidative and proteolytic
breakdown of collagen and proteoglycans [25]. Once
sequestered within the joint space, neutrophils degranu-
late and release a variety of potentially harmful enzymes
and peptides [1]. They may also undergo a respiratory
burst and generate several reactive oxygen species,
including superoxide, hydrogen peroxide, hypohalous
acids, and possibly hydroxyl radical [2, 6]. Although
these destructive oxidants have often been held partly
responsible for joint destruction, compelling evidence
that they are in fact produced within the synovium is
lacking.
The haem enzyme MPO plays a central role in oxidant
production by neutrophils. It uses superoxide and hydro-
gen peroxide to catalyse the generation of anti-bacterial
hypochlorous acid and free radicals. In plasma it oxidizes
urate to a radical that scavenges both nitric oxide and
superoxide [7, 8]. In the latter reaction a hydroperoxide
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is formed that ultimately breaks down to allantoin [7, 8].
Hypochlorous acid is the major strong oxidant generated
by neutrophils when they kill bacteria [9] and it is also
produced at sites of inflammation [10]. It reacts predom-
inantly with methionine and cysteine residues in proteins
to disrupt their tertiary structure as well promote intra- and
inter-molecular cross-links and inactivate enzymes [11].
Hypochlorous acid also targets lysine residues to form
chloramines that break down to protein carbonyls and in
the process may release toxic ammonia chloramine
(NH2Cl) [12]. Minor reactions of hypochlorous acid and
chloramines result in the chlorination of tyrosine residues
to form 3-chlorotyrosine [13]. This halogenated amino acid
is a specific biomarker of hypochlorous acid, whereas
protein carbonyls are non-specific biomarkers of oxidative
stress [14].
RA is a heterogeneous disease, in which MPO may play
a role in the pathogenesis, severity and/or outcomes.
Indeed, MPO is present at high concentrations in SF of
patients with RA. Furthermore, chlorinated IgG has been
shown to be proinflammatory [15] and the immunogenic
and arthritogenic properties of type II collagen are heigh-
tened by chlorination of this protein [16]. MPO could pos-
sibly produce hypochlorous acid in the inflamed RA joint,
but this has yet to be unequivocally demonstrated. A valid
argument against this proposal is the reported finding that
most of the enzyme was inactive in SF [17]. This finding
suggests that MPO has a limited capacity to produce oxi-
dants in RA.
Importantly with respect to outcomes in RA, MPO is a
marker of cardiovascular risk [18]. In apparently healthy
individuals, plasma MPO concentrations predict the pres-
ence of coronary artery disease as well as future risk of
coronary artery disease. Cardiovascular disease (CVD) is
recognised as an important cause of death in patients
with RA [19]. Women with RA have an increased risk of
myocardial infarction (MI) compared with women without
RA, even after adjustment for other cardiovascular risk
factors (RR 2.0; 95% CI 1.23, 3.29). Traditional cardiovas-
cular risk factors, including body mass index, diabetes,
hypertension, hypercholesterolaemia physical activity
and family history of early MI, are similar between
women with and without RA [20]. Thus RA is associated
with an increased incidence of cardiovascular disease,
which is not explained by classical cardiovascular risk fac-
tors [21]. The link between inflammation and cardiovascu-
lar disease is further supported by evidence that disease-
modifying anti-rheumatic agents such as MTX, which sup-
press the inflammatory process in RA, are associated with
lower cardiovascular mortality rates in patients with RA
[22, 23].
Given the potential of MPO to contribute to both the
pathology of RA and the associated complications of
CVD, our aims in this study were to determine whether it
is active and promotes oxidative stress in SF through the
production of hypochlorous acid. In addition, we wished
to determine the relationship between inflammatory dis-
ease activity of patients with RA and the levels of MPO in
plasma and SF.
Methods
Patients
Patients with RA, but without known cardiovascular dis-
ease, were recruited from rheumatology departments in
Christchurch Hospital, New Zealand and The Royal Devon
and Exeter Hospital Trust, UK. All patients fulfilled the
American Rheumatism Association 1987 classification cri-
teria for RA [24]. Healthy controls were randomly selected
from the Christchurch (NZ) electoral roll. Ethical approval
was obtained from the local ethics committees in New
Zealand and the UK (Upper South B Regional Ethics
Committee, Christchurch, New Zealand; North and East
Devon Research Ethics Committee, UK). All patients gave
written informed consent.
Standard demographic details were collected including
disease duration, RF and CCP status. Disease activity
was assessed using a variety of variables including ESR
and CRP, swollen joint count (SJC), tender joint count
(TJC) and DAS-28. Peripheral blood and where possible
SF were collected and processed as described previously
[25]. Patients with DAS-28 >3.2 or with joint effusion
requiring aspiration were defined as having high disease
activity (HDA) and those with DAS-28 43.2 low disease
activity (LDA).
MPO and protein oxidation assays
The concentration of MPO in plasma and SF was deter-
mined by adapting an ELISA [26]. The MPO was initially
captured with a monoclonal MPO antibody, and its activity
was determined using hydrogen peroxide and Amplex
Red. After washing the plate to remove peroxidase
reagents and products, the amount of MPO that was
bound was determined using a polyclonal MPO antibody.
MPO activity and MPO protein were compared with
standards of known concentrations, which were deter-
mined by measuring the absorbance of MPO at 430 nm
(" 89 000 M/cm/haem) [27].
3-Chlorotyrosine in proteins was determined by hydro-
lysing proteins in SF with methanesulphonic acid and
measuring the liberated amino acid along with tyrosine
by using gas chromatography with stable isotope dilution
mass spectrometry [10]. Allantoin in plasma was mea-
sured by using hydrophilic interaction chromatography
followed by stable isotope dilution mass spectrometry
as described elsewhere [8, 28].
Protein carbonyls were determined by ELISA supplied
by Zentech, Dunedin, New Zealand. Proteins in super-
natants were reacted with 2,4-dinitrophenylhydrazine,
then absorbed onto wells in an ELISA plate and probed
with an antibody raised against protein conjugated 2,4-
dinitrophenylhydrazine. The biotin-conjugated primary
antibody was then reacted with streptavidin-biotinylated
horseradish peroxidase for quantification [29].
Statistical analysis
Data were expressed as the median and inter-quartile
range (IQR). The statistical analysis of differences
between group medians was carried out using the
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MannWhitney rank sum test. Correlations were tested
using the Spearman rank order correlation method.
Results
Patient demographics
Seventy-seven patients were recruited, of which 49
(63.6%) had HDA disease (DAS-28 >3.2). Patient demo-
graphics for the whole group and those with HDA and LDA
disease are outlined in Table 1. Of the 49 patients with
HDA disease, 26 (53.1%) had paired plasma and SF
samples.
MPO is increased in patients with RA compared with
healthy controls
Plasma MPO protein was significantly higher in patients
with RA compared with healthy controls (10.8 ng/ml, IQR
7.214.2; P< 0.05) (Fig. 1). However, there was no signifi-
cant difference in plasma MPO protein concentrations be-
tween RA patients with HDA or LDA [HDA 27.9 ng/ml
(20.234.1 ng/ml) vs LDA 22.1 ng/ml (16.934.9 ng/ml);
P> 0.05] (Fig. 1A). The median specific activity of MPO
(i.e. the ratio of MPO activity to MPO protein) was
61% (IQR 2980%; n= 28) in healthy controls, 45%
(IQR 2657%; n= 26) in patients with LDA RA and 39%
(IQR 2565%; n= 29) in RA patients with HDA (Fig. 1B).
There was no significant difference between these groups
(P= 0.14), but the values indicated that the specific activity
of detectable MPO in plasma is highly variable. Values
of MPO protein <10 ng/ml were excluded from this
calculation to avoid erroneously over-estimating the
specific activity.
Relationship between disease activity
and MPO plasma concentration
There were statistically significant correlations between
plasma MPO protein concentrations and SJC (r= 0.27;
P= 0.023), TJC (r= 0.38; P< 0.001) and CRP (r= 0.31;
P= 0.009) but not ESR (r= 0.23; P= 0.06). There was
also a statistically significant correlation between DAS-
28 and plasma MPO protein (r= 0.35; P= 0.005) (Fig. 2).
MPO is significantly higher in SF compared
with plasma of patients with RA
MPO protein was also detected in SF from patients with
RA (Fig. 3A). It was 20-fold higher in SF [median
624.0 ng/ml (IQR 258.42433.0)] than in plasma
[30.2 ng/ml (IQR 25.150.9)]. Using paired SF and
plasma samples (n= 26), the difference was found to be
highly significant (P< 0.0001). In general, the MPO protein
present in SF retained most of its activity (Fig. 3B). The
levels of MPO in SF did not correlate with disease activity.
Evidence for oxidative stress in RA
Protein carbonyls were measured as a non-specific
marker of oxidative stress and were present in both
plasma and SF. Plasma protein carbonyls were measured
in 120 healthy controls [median age 67.5 years (IQR
57.276) and 72.5% male] and compared with those in
patients with RA. They were significantly higher in patients
with RA than in healthy controls (13.0 pmol/mg protein,
TABLE 1 Demographics of patients with active RA and inactive RA
All RA
patients
(n=77)
HDA RA
(DAS-28 >3.2)
(n=49)
LDA RA
(DAS-28 43.2)
(n=28)
Age, years 54.7 (2282) 54.5 (2382) 54.9 (2374)
Female, % 71.4 73.5 67.9
TJC28 3.9 (027) 5.8 (027) 0.5 (02)
SJC28 4.0 (024) 6.1 (024) 0.36 (04)
DAS-28 (ESR) 3.81 (0.077.66) 4.9 (2.87.66) 1.84 (0.073.03)
ESR, mm/h 29.6 (199) 39.1 (299) 9.8 (132)
CRP, mg/l 26.2 (0206) 38.9 (0206) 5 (022)
RF positive, n (%) 47/71 (66.2) 25/43 (58.1) 22/28 (78.6)
CCP positive, n (%) 37/45 (82.2) 17/22 (77.3) 20/23 (86.9)
Erosive disease, n (%) 46/76 (60.5) 29/28 (60.4) 17/28 (60.7)
MTX, n (%) 41 (53.2) 22 (44.9) 19 (67.9)
Salazopyrin, n (%) 15 (19.5) 8 (16.3) 7 (25)
HCQ, n (%) 14 (18.2) 9 (18.4) 5 (17.9)
Adalimumab, n (%) 8 (10.4) 6 (12.2) 2 (7.1)
LEF, n (%) 14 (18.2) 8 (16.3) 6 (21.4)
Prednisone, n (%) 20 (26) 15 (30.6) 5 (17.9)
AZA, n (%) 13 (16.9) 12 (24.5) 1 (3.6)
Rituximab, n (%) 1 (1.3) 1 (2.0) 0
IM Gold, n (%) 1 (1.3) 0 1 (3.6)
NSAID, n (%) 32 (41.6) 24 (49) 8 (28.6)
Data are expressed as mean (range) unless otherwise stated.
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IQR 050; P< 0.05) (Fig. 4A). However, there was no sig-
nificant difference between RA patients with HDA and
those with LDA (51.0 pmol/mg protein; IQR 25.170.1 vs
37.7 pmol/mg protein, 21.160.2; P> 0.05) (Fig. 4A).
Plasma protein carbonyls were not correlated with
plasma MPO concentrations or disease activity.
Allantoin, a biomarker of urate oxidation [7, 8], was
elevated in plasma from patients compared with controls
(2.0 mM, IQR 1.43.6; P< 0.001). There was no signifi-
cant difference between concentrations in patients with
HDA (3.5 mM, IQR 3.05.6 mM) and LDA (3.7 mM, IQR
2.95.3mM). Allantoin concentrations were not correlated
with MPO or protein carbonyls in plasma.
Protein carbonyls were significantly higher in SF of
patients with RA (47.0 pmol/mg protein, IQR 3659.5;
P< 0.05) than in plasma from healthy controls but were
not elevated compared with those in plasma from patients
with LDA or HDA (Fig. 4A). In SF, protein carbonyls were
associated with MPO concentration (Fig. 4B) (r= 0.40,
P= 0.019, n= 34). They were not associated with markers
of disease activity.
Evidence of hypochlorous acid production and
oxidative stress in RA
3-Chlorotyrosine, the specific biomarker of hypochlorous
acid, was detected in proteins from SF using stable iso-
tope dilution mass spectrometry (40.5 mmol/mol tyrosine,
IQR 37.058.0, n= 18). In accord with a previous study
[10], detection of 3-chlorotyrosine in proteins was vali-
dated by the findings that it co-eluted with an authentic
standard, had the correct molecular mass and fragmen-
tation pattern, and its stable isotopes were present in the
expected 3 : 1 ratio for a chlorine-containing molecule.
Levels of 3-chlorotyrosine were related to the concentra-
tion of MPO (r= 0.69, P= 0.001, n= 18) (Fig. 5A). Also, they
were strongly correlated with levels of protein carbonyls
(r= 0.66, P= 0.003, n= 18) (Fig. 5B). This chlorinated
amino acid could not be detected in plasma proteins.
Discussion
Reactive oxygen species are often implicated in the path-
ology of RA [30, 31], yet until now there has been a paucity
of solid data to establish which oxidants are actually pro-
duced in the inflamed joint. Detection of 3-chlorotyrosine
confirms that hypochlorous acid is produced in SF and
reacts with proteins. There is no other known biological
reaction that produces 3-chlorotyrosine, and MPO is the
only human enzyme capable of generating hypochlorous
acid [14]. Hence, the strong correlation between
3-chlorotyrosine and the levels of MPO indicates that
this enzyme catalyses the production of hypochlorous
acid in SF. Furthermore, the association of protein
FIG. 1 MPO protein and specific activity in plasma.
(A) Plasma MPO concentration in RA patients with high or
low disease activity compared with healthy controls (HC).
*P< 0.05 cf. control MPO protein. (B) Specific activity of
MPO in plasma samples.
FIG. 2 Relationship between DAS-28 and MPO in patients
with RA.
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carbonyls with both MPO and 3-chlorotyrosine suggests
that hypochlorous acid is a major driver of the oxidative
damage that occurs to proteins in the inflamed joint. This
finding has important implications for RA because hypo-
chlorous acid is the strongest two-electron oxidant pro-
duced in vivo. It is much more reactive than either
hydrogen peroxide or peroxynitrite [32]. It readily oxidizes
cysteine and methionine residues as well as cross-linking
and fragmenting proteins [33], inactivating a1-antiprotease
inhibitor [11] and adversely affecting the functions of
low-density lipoprotein (LDL) and high-density lipoprotein
(HDL) [34]. Given its extreme and diverse reactivity, it is
likely that hypochlorous acid contributes to the tissue
FIG. 4 Biomarkers of oxidative stress in RA.
(A) Plasma protein carbonyls in healthy controls and
RA patients with high and low disease activity. Also
shown are protein carbonyls in SF from patients with
RA. (B) Plasma allantoin concentrations in healthy controls
and RA patients with HDA and LDA. (C) Correlation of
protein carbonyls with MPO in SF of patients with RA.
*P< 0.05 compared with healthy controls.
FIG. 3 SF and plasma MPO concentrations from patients
with RA.
(A) MPO protein was measured in paired SF and
plasma samples from 26 patients, revealing higher MPO
protein concentrations in SF compared with plasma.
(B) Relationship between MPO protein and activity in SF
from patients with RA.
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damage that occurs in patients with RA. Thus, targeting
specific inhibitors, such as 2-thioxanthines, against MPO
would be expected to lower oxidative stress within the
inflamed joint [35].
In contrast to a previous report [17], we found that the
MPO present in most SF samples had retained a large
proportion of its activity and therefore was capable of
producing hypochlorous acid. In plasma, however, MPO
activity was highly variable and on average was 50%
active. MPO may have been inactivated by the oxidants
it generates or inhibited by plasma proteins such as cer-
uloplasmin [36]. The reason for the low MPO activity in
plasma requires further investigation. This result suggests
that MPO has a limited capacity to generate oxidants as it
will eventually lose much of its activity. Inactivation of
MPO may not have been apparent in SF because it was
present at enormous concentrations compared with
plasma and was likely to be continually replenished by
activated neutrophils present within the inflamed joint.
In agreement with previous studies of patients with in-
flammatory joint disease [3739], we found that patients
with RA have increased plasma MPO concentrations. We
also showed that plasma MPO concentrations are signifi-
cantly correlated with disease activity. This is in contrast
to a recent study that found no correlation between
plasma MPO concentrations and DAS-28 score [39].
This may reflect a greater range of DAS-28-ESR scores
in our study compared with the earlier work. In this work,
the better correlation of disease activity with plasma MPO
rather than with MPO in SF may reflect the systemic in-
flammatory state of patients with RA [40]. Alternatively,
this finding may have arisen because plasma concentra-
tions are more likely to reflect cumulative release of the
enzyme from neutrophils and its accumulation due to its
adherence to the endothelium [41]. In contrast, the MPO
measured in SF is most likely representative of that re-
cently released from activated cells.
Protein carbonyls were present in plasma at similar
levels to those in SF yet there was no detectable 3-chloro-
tyrosine in plasma. Others have suggested that because
3-chlorotyrosine is susceptible to oxidation by peroxyni-
trite and hypochlorous acid, its levels may be underesti-
mated at sites of chronic inflammation [42]. Previously,
however, it was demonstrated that 3-chlorotyrosine
should be present in plasma proteins if hypochlorous
acid was solely responsible for producing protein car-
bonyls at the levels we detected [26]. Consequently, we
must conclude that hypochlorous acid was unlikely to be
responsible for producing protein carbonyls in plasma
proteins. This does not rule out the involvement of MPO
in promoting oxidative stress via production of other oxi-
dants such as hypothiocyanous acid, free radicals and
urate hydroperoxide [7, 8]. Indeed, allantoin, the oxidation
product of urate, was elevated in the plasma of patients
with RA, which confirms that these patients had increased
levels of oxidative stress. It is not possible to determine
whether allantoin was derived from the direct oxidation of
urate by MPO [7, 8] or via other oxidants. The lack of
correlation between MPO and allantoin should not be
used to exclude this enzyme because the turnover of sol-
uble allantoin is expected to be very different from that of
MPO, which is mostly adhered to the endothelium [41].
MPO and hypochlorous acid may also contribute to the
complications of RA. RA is associated with an increase in
mortality, particularly in those with more severe disease
and extra-articular manifestations [43]. This increase in
mortality is largely due to an increase in cardiovascular
deaths, with a recent meta-analysis indicating that cardio-
vascular mortality is increased by 50% in RA patients
compared with the general population [44]. This increase
in cardiovascular disease and mortality does not appear
to be due to an increase in traditional cardiovascular risk
factors such as family history, smoking, hypertension and
hyperlipidaemia. The quest for biomarkers that can pre-
dict disease and/or treatment outcomes is a key research
focus in RA. However, to date no reliable soluble bio-
markers have been identified.
MPO has been identified as another marker of CVD risk.
Within the vascular system, MPO may contribute to the
pathogenesis of CVD as well as to acute cardiovascular
FIG. 5 Protein chlorination in SF.
The association of protein chlorination with (A) MPO and
(B) protein carbonyls in SF from patients with RA.
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events. MPO converts LDL into a form which promotes
foam cell formation within atherosclerotic plaques. It may
also promote formation of a dysfunctional form of HDL,
which has a reduced ability to promote cellular efflux of
cholesterol [34]. The involvement of MPO in the pathogen-
esis of CVD is supported by evidence that elevated MPO
concentrations are an independent risk factor for future
cardiovascular events in healthy individuals [45]. MPO
and metalloproteinases contribute to atherosclerotic
plaque rupture by degrading the collagen layer of the ath-
eroma [46].
Our findings that MPO is elevated in RA and contributes
to oxidative stress in these patients provide a potential
mechanism for the increase in CVD observed in patients
with RA. Interestingly, treatment with infliximab has been
shown to reduce disease activity and reduce plasma MPO
concentrations [38]. Whether MPO is an independent pre-
dictor of CVD in patients with RA has not been formally
examined. Large prospective clinical trials will be required
to determine whether MPO is a reliable biomarker for the
prediction of CVD in RA, where MPO may be increased by
the systemic inflammatory process, and to determine
whether suppression of inflammation by DMARDs is asso-
ciated with reduction of MPO and CVD risk.
Rheumatology key messages
. MPO is associated with oxidative stress in RA.
. Hypochlorous acid is produced in the inflamed
joints of patients with RA.
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